Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
Health Management AssociatesMay 15, 2025

Trump's Drug Pricing Executive Order: What It Means for Health Stakeholders

HMA experts summarize President Trump's May 2025 executive order aiming to tie U.S. drug prices to lower international benchmarks, reviving concepts from his first-term Most Favored Nation and International Pricing Index proposals. The order directs trade agencies and HHS to pursue manufacturer and regulatory actions, including exploring direct-to-consumer sales at MFN prices, though its ultimate implementation and legal durability remain uncertain. While centered on Medicare Part B and broader pharmaceutical pricing, the policy could have downstream implications for Medicaid drug pricing and rebate dynamics that pharmacy and finance teams at MCOs should monitor.

Pharmacy

Read the full analysis at Health Management Associates →

This is outside commentary from Health Management Associates, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Health Management Associates

← Analysis & Perspectives

Get the daily briefing.